Globe Newswire07.23.18
Daxor Corporation, a medical instrumentation and biotechnology company focused on blood volume measurement, has appointed Kathryn A. Kornafel as vice president of Marketing and Commercial Development.
"Kathryn’s marketing experience within the diagnostic, cardiovascular and point-of-care arenas position her to support Daxor’s aggressive sales goals,” said Michael Feldschuh, CEO of Daxor. “We look forward to leveraging her more than 25 years of experience to drive awareness and educate healthcare professionals regarding our 98 percent accurate BVA-100. Clinical studies have demonstrated strong patient outcomes from blood volume-guided therapy in heart failure and critical care.”
Before joining Daxor, Kornafel has held leadership roles in global marketing, business development, and sales with major international in-vitro diagnostic device companies, including HemoCue and Ortho Clinical Diagnostics. In addition to her business experience, Kornafel is an American Society of Clinical Pathology-certified medical technologist with clinical lab experience in hematology and microbiology. She has a bachelor’s degree in biology from University of Delaware and a bachelor of science degree in medical technology from Thomas Jefferson University.
Daxor Corporation is a commercial-stage medical instrumentation and biotechnology company. The New York, N.Y.-based company manufactures the BVA-100 Blood Volume Analyzer, the only instrument cleared by the U.S. Food and Drug Administration to provide rapid direct measurement of a patient’s blood volume and optimal volume.
"Kathryn’s marketing experience within the diagnostic, cardiovascular and point-of-care arenas position her to support Daxor’s aggressive sales goals,” said Michael Feldschuh, CEO of Daxor. “We look forward to leveraging her more than 25 years of experience to drive awareness and educate healthcare professionals regarding our 98 percent accurate BVA-100. Clinical studies have demonstrated strong patient outcomes from blood volume-guided therapy in heart failure and critical care.”
Before joining Daxor, Kornafel has held leadership roles in global marketing, business development, and sales with major international in-vitro diagnostic device companies, including HemoCue and Ortho Clinical Diagnostics. In addition to her business experience, Kornafel is an American Society of Clinical Pathology-certified medical technologist with clinical lab experience in hematology and microbiology. She has a bachelor’s degree in biology from University of Delaware and a bachelor of science degree in medical technology from Thomas Jefferson University.
Daxor Corporation is a commercial-stage medical instrumentation and biotechnology company. The New York, N.Y.-based company manufactures the BVA-100 Blood Volume Analyzer, the only instrument cleared by the U.S. Food and Drug Administration to provide rapid direct measurement of a patient’s blood volume and optimal volume.
